Polypid Ltd is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative drug delivery technologies and therapies for various medical applications. The company was founded in 2008 by Dr. Amir Weisberg and Dr. Shai Rosenberg. Polypid's mission is to improve patient outcomes and quality of life by addressing the limitations of conventional drug delivery methods through its proprietary platform technology. Polypid Ltd is a publicly traded company listed on the Nasdaq Global Market under the ticker symbol "PYPD."
The company's flagship product is the D-PLEX™ platform, a biodegradable polymer-based drug delivery system. D-PLEX™ is designed to enable controlled and sustained release of medications over an extended period, offering potential advantages over traditional drug delivery methods, such as improved efficacy, reduced side effects, and reduced dosing frequency.
Polypid focuses on developing therapies in various therapeutic areas, including infectious diseases, oncology, and inflammatory conditions. One of the key applications of its D-PLEX™ platform is for the prevention of surgical site infections, which can significantly impact patient recovery and healthcare costs.
In addition to its research and development activities, Polypid collaborates with pharmaceutical and biotechnology companies to explore potential applications of its drug delivery platform with a variety of therapeutic agents. These partnerships enhance the company's capabilities and widen its potential market reach.